BackgroundThe soluble form of cellular prion protein (PrPC) in plasma has been investigated as a biomarker in multiple conditions, yet its relationship with ischemic stroke severity remains unclear. Soluble PrPC is also implicated in immune-cell activation and inflammatory regulation.
Here, we examined whether plasma soluble PrPC is associated with stroke severity and circulating CD4+ T cell immune responses in patients with acute ischemic stroke.MethodsIn this single-center prospective cohort study, we consecutively enrolled patients with acute ischemic stroke admitted to the Department of Neurology, The First Hospital of Jilin University (Changchun, China) between June 2023 and October 2024 within 48 h of symptom onset (for wake-up stroke, onset was defined as the last known well). Fasting venous blood was collected the morning after admission.
Stroke severity was categorized by admission NIHSS as mild (≤6) or moderate-to-severe (>6), and volunteers from the Health Examination Center served as controls.
Frontiers in Immunology published a clinical update in Infectious Disease on 22 Apr 2026.
The item focuses on Plasma soluble cellular prion protein reflects ischemic stroke severity and is associated with circulating CD4+ T cell immune responses.
Review the original article for the full source wording and details.